Type of resource
The following are recommendations and best practices to consider when developing plans for safely restarting mass drug administration (MDA) campaigns in the context of COVID-19. This document is meant to supplement WHO’s guidance note entitled, Considerations for implementing mass treatment, active case-finding and population-based surveys for neglected tropical diseases in the context of the COVID-19 pandemic, released on 27 July, 2020.
This document should only be used after a thorough COVID-19 risk-benefit assessment (including assessment of community acceptance and readiness) has been completed and the decision has been made to proceed with MDA. Considerations for a risk-benefit assessment can be found in the WHO guidance cited above.